| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/24/2000 | EP1002069A1 Peptides containing the motif igd and their use as cell migration modulators |
| 05/24/2000 | EP1002065A1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 05/24/2000 | EP1002064A1 A modified polypeptide |
| 05/24/2000 | EP1002051A2 PROBIOTIC STRAINS FROM $i(LACTOBACILLUS SALIVARIUS) AND ANTIMICROBIAL AGENTS OBTAINED THEREFROM |
| 05/24/2000 | EP1001990A1 Protein that binds trail |
| 05/24/2000 | EP1001989A1 Prolactin secretion modulator |
| 05/24/2000 | EP1001986A2 Pharmaceuticals for modulating hormone responsiveness |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS |
| 05/24/2000 | EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS |
| 05/24/2000 | EP1001982A1 Cardiotrophin-like cytokine |
| 05/24/2000 | EP1001979A1 Cyclic azapeptides with angiogenic effect |
| 05/24/2000 | EP1001978A1 Angiotensin derivatives |
| 05/24/2000 | EP1001977A2 Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| 05/24/2000 | EP1001976A2 Peptides having potassium channel opener activity |
| 05/24/2000 | EP1001975A1 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001972A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001971A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001969A1 Peptidomimetic derivatives suicidal inhibitors of the hiv proliferation |
| 05/24/2000 | EP1001967A1 Componds and methods for treating and screening viral reactivation |
| 05/24/2000 | EP1001966A1 A senescence gene and its use in the treatment of cancer and other diseases |
| 05/24/2000 | EP1001965A1 Tissue plasminogen activator-like protease |
| 05/24/2000 | EP1001964A1 Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides |
| 05/24/2000 | EP1001932A1 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
| 05/24/2000 | EP1001815A1 Vectors derived from antibodies for transferring substances into cells |
| 05/24/2000 | EP1001814A1 Controlled release microencapsulated ngf formulation |
| 05/24/2000 | EP1001810A1 Pharmaceutical composition with neurotrophic-like biological activity |
| 05/24/2000 | EP1001809A1 Decreased fat absorption with an anti-lipase antibody |
| 05/24/2000 | EP1001807A1 Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes for prevention/treatment of cancer or infectious diseases |
| 05/24/2000 | EP1001806A1 Cellular vesicle called ''exosome'', preparation and use thereof in immune stimulation |
| 05/24/2000 | EP1001805A1 Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof |
| 05/24/2000 | EP1001804A1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 05/24/2000 | EP1001803A1 Pharmaceutical compound preparation comprising a parathyroid hormone preparation an a calcium/phosphate preparation |
| 05/24/2000 | EP1001802A1 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
| 05/24/2000 | EP1001801A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 05/24/2000 | EP1001800A2 Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| 05/24/2000 | EP1001799A1 Pharmaceutical composition containing peptichemio |
| 05/24/2000 | EP1001798A1 Method for preventing or treating a human immunodeficiency virus infection |
| 05/24/2000 | EP1001796A1 Antacid and papain combination |
| 05/24/2000 | EP1001795A1 Vasoprotective recombinant adenovirus vector containing a human tfpi gene |
| 05/24/2000 | EP1001768A1 Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| 05/24/2000 | EP1001764A1 Heterocyclic amide compounds as cell adhesion inhibitors |
| 05/24/2000 | EP1001750A1 Stable particulate complexes with neutral or negative globale charge of lamellar structure |
| 05/24/2000 | EP1001745A1 Artificial tear formulation |
| 05/24/2000 | EP1001737A1 Intra-oral antioxidant preparations |
| 05/24/2000 | EP1001736A1 STARCH BINDING DOMAINS (SBDs) FOR ORAL CARE PRODUCTS |
| 05/24/2000 | EP0808332B1 Method for preparing collagen from cnidarians, and resulting cosmetic compositions |
| 05/24/2000 | EP0804070B1 Process of isolation of proteins from milk |
| 05/24/2000 | EP0793674B1 Human neutrophil elastase inhibitors |
| 05/24/2000 | EP0725629B1 Liposomal defensins |
| 05/24/2000 | EP0724452B1 Pharmaceutical composition containing cyclosporine a, a vitamine e derivative and an emulsifier |
| 05/24/2000 | EP0720620B1 Glutathione analogs and paralog panels comprising glutathione mimics |
| 05/24/2000 | EP0687270B1 Osteogenic growth oligopeptides and pharmaceutical compositions containing them |
| 05/24/2000 | EP0671879B1 Prevention of injury and degeneration of photoreceptors by neurotrophic factors |
| 05/24/2000 | EP0652764B1 Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens |
| 05/24/2000 | EP0529031B1 Improved inhibitors of thrombin |
| 05/24/2000 | EP0497911B1 Recombinant production of lactoperoxidase |
| 05/24/2000 | CN1254378A Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors |
| 05/24/2000 | CN1254376A 端粒酶逆转录酶 Telomerase reverse transcriptase |
| 05/24/2000 | CN1254375A Motilin homologs |
| 05/24/2000 | CN1254374A Inhibitors of cellulolytic, xylanolytic and 'beta'-glucanolytic enzymes |
| 05/24/2000 | CN1254347A Analogs of parathyroid hormone |
| 05/24/2000 | CN1254346A Calcitonin receptor-binding peptides |
| 05/24/2000 | CN1254345A Serine protease inhibitors |
| 05/24/2000 | CN1254294A Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| 05/24/2000 | CN1254291A Use of leptin antagonists for treatment of diabetes |
| 05/24/2000 | CN1254290A Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 05/24/2000 | CN1254284A Activated protein C formulations |
| 05/24/2000 | CN1253832A Metabolism-supporting preparation for curing hepatic failure and its preparation method |
| 05/24/2000 | CN1253734A Bittersquash extraxt sugar-reducing milk powder and its preparation process |
| 05/24/2000 | CN1052733C Immuno-stimulatory monoclonal antibodies |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052730C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052655C Human relaxin formulation |
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066724 Human endometrial specific steroid-binding factor I, II and III |
| 05/23/2000 | US6066719 Immunoglobulin heavy chain fragment associated with two light chains which each comprise a variable domain and form two functional antigen binding positions; for use in isolation of antibodies |
| 05/23/2000 | US6066718 Culturing host encoding dna capable of expressing antibody against immunoglobulin e, isolating, and conjugating with an enzyme, a fluorescent or chemiluminescent marker, a cytotoxic or cytostatic substance, radioactive label or others |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066676 Pharmaceutical composition and methods for using it |
| 05/23/2000 | US6066639 Antitumor agents |
| 05/23/2000 | US6066626 Supplying active human galactosidase to cells |
| 05/23/2000 | US6066625 Enzyme inhibitor; modulators of gene expression |
| 05/23/2000 | US6066624 Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes |
| 05/23/2000 | US6066622 Immunomodulating peptides and methods of use |
| 05/23/2000 | US6066621 Response inhibiting peptide |
| 05/23/2000 | US6066620 Mixture with surfactant |
| 05/23/2000 | US6066619 Non-aqueous protic peptide formulations |
| 05/23/2000 | US6066618 Regulation of cell proliferation and differentiation using peptides |
| 05/23/2000 | US6066617 Polypeptide |
| 05/23/2000 | US6066616 Administering octreotide |
| 05/23/2000 | US6066502 Endothelin converting enzyme (ECE) |
| 05/23/2000 | US6066500 Antisense modulation of Beta catenin expression |
| 05/23/2000 | US6066498 Compositions for the treatment and diagnosis of immune disorders |
| 05/23/2000 | US6066477 Method of producing glucosylated saccharides with kojibiose phosphorylase |
| 05/23/2000 | US6066475 Parathyroid cytosolic autoantigens recognized by autoantibodies from patients with acquired hypoparathyroidism |
| 05/23/2000 | US6066469 Cloning, expression, and uses of human lactoferrin |